BR112021008548A2 - tratamento e diagnóstico de doenças oculares mediadas por autoanticorpos - Google Patents

tratamento e diagnóstico de doenças oculares mediadas por autoanticorpos Download PDF

Info

Publication number
BR112021008548A2
BR112021008548A2 BR112021008548-3A BR112021008548A BR112021008548A2 BR 112021008548 A2 BR112021008548 A2 BR 112021008548A2 BR 112021008548 A BR112021008548 A BR 112021008548A BR 112021008548 A2 BR112021008548 A2 BR 112021008548A2
Authority
BR
Brazil
Prior art keywords
ocular
disease
eye
igg
ophthalmic formulation
Prior art date
Application number
BR112021008548-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Sandeep Jain
Original Assignee
The Board Of Trustees Of The University Of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The University Of Illinois filed Critical The Board Of Trustees Of The University Of Illinois
Publication of BR112021008548A2 publication Critical patent/BR112021008548A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112021008548-3A 2018-11-08 2019-11-08 tratamento e diagnóstico de doenças oculares mediadas por autoanticorpos BR112021008548A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862757641P 2018-11-08 2018-11-08
US62/757,641 2018-11-08
US201962855253P 2019-05-31 2019-05-31
US62/855,253 2019-05-31
PCT/US2019/060566 WO2020097528A1 (en) 2018-11-08 2019-11-08 Treatment and diagnosis of autoantibody-mediated eye diseases

Publications (1)

Publication Number Publication Date
BR112021008548A2 true BR112021008548A2 (pt) 2021-08-03

Family

ID=69056109

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021008548-3A BR112021008548A2 (pt) 2018-11-08 2019-11-08 tratamento e diagnóstico de doenças oculares mediadas por autoanticorpos

Country Status (10)

Country Link
US (1) US20220062337A1 (cg-RX-API-DMAC7.html)
EP (1) EP3877406A1 (cg-RX-API-DMAC7.html)
JP (2) JP7624220B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210093274A (cg-RX-API-DMAC7.html)
CN (1) CN113631570B (cg-RX-API-DMAC7.html)
AU (1) AU2019377552B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008548A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118367A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005352A (cg-RX-API-DMAC7.html)
WO (1) WO2020097528A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100002306A1 (it) * 2021-02-03 2022-08-03 Univ Degli Studi Roma La Sapienza Procedimento e kit per la diagnosi in vitro della sindrome da anticorpi anti-fosfolipidi
US11951123B2 (en) * 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
WO2023201283A2 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Methods of producing plasma or serum and uses thereof
WO2024077068A1 (en) * 2022-10-06 2024-04-11 Oklahoma Medical Research Foundation Anti-vimentin antibodies are associated with higher severity of sjögren's syndrome
WO2024136368A1 (ko) * 2022-12-21 2024-06-27 건국대학교 산학협력단 α-2,6-시알산화 면역글로불린의 안구 건조증 또는 염증성 안과 질환의 예방 또는 치료 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984492B2 (en) 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
CA2888519C (en) 2012-10-17 2023-02-21 Liverpool School Of Tropical Medicine Immunomodulatory proteins
US9107906B1 (en) * 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Also Published As

Publication number Publication date
WO2020097528A1 (en) 2020-05-14
US20220062337A1 (en) 2022-03-03
MX2021005352A (es) 2021-09-14
KR20210093274A (ko) 2021-07-27
AU2019377552A1 (en) 2021-05-27
CA3118367A1 (en) 2020-05-14
AU2019377552B2 (en) 2026-07-23
EP3877406A1 (en) 2021-09-15
JP2022512946A (ja) 2022-02-07
CN113631570B (zh) 2026-06-02
JP2025061211A (ja) 2025-04-10
CN113631570A (zh) 2021-11-09
JP7624220B2 (ja) 2025-01-30

Similar Documents

Publication Publication Date Title
JP7624220B2 (ja) 自己抗体媒介性眼疾患の治療および診断
Toops et al. Cholesterol-mediated activation of acid sphingomyelinase disrupts autophagy in the retinal pigment epithelium
US20210322457A1 (en) Treatment and diagnosis of ocular surface disorders
CN107206009B (zh) 用于治疗视觉障碍的组合物和方法
ES2835274T3 (es) Composiciones farmacéuticas que contienen un antagonista de la integrina alfa 4 para el tratamiento de afecciones inflamatorias oculares
JP2022041802A (ja) Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物
JP2022512946A5 (cg-RX-API-DMAC7.html)
CN108472372A (zh) 结合不动杆菌的抗体结合剂及其用途
Lee et al. Pre-clinical studies of a novel bispecific fusion protein targeting C3b and VEGF in neovascular and nonexudative AMD models
CA2967432A1 (en) Animal model for dry eye and methods of use of such animals
US20230365665A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
US12268706B2 (en) Hyaluronic acid for relief of idiopathic ocular pain
Kivinen The role of autophagy in age-related macular degeneration
WO2023220676A2 (en) Formulation for treating dry eye disease
Erdağ et al. Effects of in vivo and in vitro administration of neuro-Behcet’s disease IgG
RU2845362C2 (ru) Лечение и диагностика опосредованных аутоантителами глазных заболеваний
Foster et al. Ocular cicatricial pemphigoid
WO2022155322A1 (en) Methods for the detection and treatment of proteinopathies
EP4640702A1 (en) Use of alpha-2,6-sialylated immunoglobulin in preventing or treating dry eye syndrome or inflammatory eye diseases
Muna et al. Ocular cicatricial pemphigoid
EP4615452A1 (en) Cgrp/ramp1 blockade to treat endometriosis-associated pain and reduce endometriosis lesions
RU2021116163A (ru) Лечение и диагностика опосредованных аутоантителами глазных заболеваний
Saw The role of inflammation and fibroblasts in conjunctival scarring in ocular mucous membrane pemphigoid

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]